Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA7 | P43166 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3754193 | 0.78 | VCP (0.34) | — | |
| SCHEMBL3751594 | 0.78 | CHRNA3 (0.41) | NPC1MAPTL3MBTL1 | |
| SCHEMBL14938867 | 0.78 | NR4A1 (0.42) | NPC1MAPTRAB9ACA12CA1 | |
| SCHEMBL29492090 | 0.78 | NR4A1 (0.42) | NPC1MAPTRAB9ACA12CA1 | |
| SCHEMBL30250475 | 0.76 | CA1 (0.53) | NPC1MAPTRAB9ACA12CA1 | |
| SCHEMBL1134723 | 0.76 | CA1 (0.53) | NPC1MAPTRAB9ACA12CA1 | |
| SCHEMBL1045536 | 0.73 | NOTUM (0.39) | NPC1MAPTRAB9A | |
| SCHEMBL3160240 | 0.73 | SMN1; SMN2 (0.33) | NPC1MAPTRAB9A | |
| SCHEMBL5831665 | 0.73 | NPC1 (0.31) | NPC1MAPTRAB9A | |
| SCHEMBL29599189 | 0.70 | APEX1 (0.38) | NPC1MAPTRAB9ACA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7342031-B2 | Thiadiazole compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2008-03-11 | — | — | US | disclosed |
| US-20070293510-A1 | Thiadiazole compounds and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED ( A JAPANESE CORPORATION) (JP) | 2007-12-20 | — | — | US | disclosed |
| US-7273879-B2 | Thiadiazole compounds and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2007-09-25 | — | — | US | disclosed |
| US-20060014962-A1 | Thiadiazole compound and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-01-19 | — | — | US | disclosed |
| US-20050215578-A1 | Thiadiazole compounds and use thereof | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2005-09-29 | — | — | US | disclosed |
| EP-1550661-A1 | THIADIAZOLE COMPOUND AND USE THEREOF | Sumitomo Chemical Company, Limited (JP) | 2005-07-06 | — | — | EP | disclosed |
| EP-1475374-A1 | THIADIAZOLE COMPOUNDS AND USE THEREOF | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-11-10 | — | — | EP | disclosed |
| US-5401768-A | Prostaglandin derivative, antiulcer, hypotensive, anticoagulant | TORAY INDUSTRIES, INC. (JP) | 1995-03-28 | — | — | US | disclosed |
| EP-0365678-B1 | 2,5,6,7-TETRANOR-4,8-INTER-m-PHENYLENE PGI 2 DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND USE THEREOF | TORAY INDUSTRIES (JP) | 1994-01-05 | — | — | EP | disclosed |
| EP-0389162-B1 | 2,5,6,7-Tetranor-4,8-inter-m-phenylene PGI2 derivatives | TORAY INDUSTRIES (JP) | 1993-12-08 | — | — | EP | disclosed |
| US-5086071-A | Improved chemical stability and ppotent in vivo | TORAY INDUSTRIES, INC. (JP) | 1992-02-04 | — | — | US | disclosed |
| EP-0232776-B1 | 2,5,6,7-TETRANOR-4,8-INTER-M-PHENYLENE PGI2 DERIVATIVES | TORAY INDUSTRIES, INC. (JP) | 1990-10-24 | — | — | EP | disclosed |
| EP-0389162-A1 | 2,5,6,7-Tetranor-4,8-inter-m-phenylene PGI2 derivatives | TORAY INDUSTRIES, INC. (JP) | 1990-09-26 | — | — | EP | disclosed |
| EP-0365678-A1 | 2,5,6,7-TETRANOR-4,8-INTER-m-PHENYLENE PGI 2 DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 1990-05-02 | — | — | EP | disclosed |
| US-4775692-A | ANTILIPEMIC, ANTICOAGULANT, HYPOTENSIVE, ANTISECRETORY AND ANTIULCER AGENT | TORAY INDUSTRIES, INC. (JP) | 1988-10-04 | — | — | US | disclosed |
| EP-0232776-A2 | 2,5,6,7-tetranor-4,8-inter-m-phenylene PGI2 derivatives | TORAY INDUSTRIES, INC. (JP) | 1987-08-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215578-A1 | Thiadiazole compounds and use thereof | C5, C3AR1, TH | NPC1 3108/4885MAPT 4618/4885RAB9A 1998/4885 |
| US-20060014962-A1 | Thiadiazole compound and use thereof | CBR3, TH, CYP2E1 | NPC1 3418/4885MAPT 3930/4885RAB9A 1437/4885 |
| US-20070293510-A1 | Thiadiazole compounds and use thereof | C5, C3AR1, TH | NPC1 3133/4885MAPT 4589/4885RAB9A 2211/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.